Tylosin

Verify with FDA CVM →

347 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
347
Total Reports
62
Deaths Reported
1790.0%
Death Rate

Active Ingredients

Tylosin

Administration Routes

OralUnknownParenteralIntramuscularSubcutaneousCutaneousTopicalIntraocularOtherRespiratory (Inhalation)

Species Affected

Dog 144
Human 51
Unknown 36
Chicken 34
Cattle 28
Pig 22
Cat 15
Turkey 6
Other Birds 4
Horse 3

Most Affected Breeds

Unknown 89
Chicken (unknown) 28
Pig (unknown) 12
Shih Tzu 10
Retriever - Labrador 9
Cattle (unknown) 8
Dog (unknown) 6
Turkey (unknown) 6
Retriever - Golden 6
Crossbred Canine/dog 6

Most Reported Reactions

Diarrhoea 51
Death 44
Lack of efficacy (bacteria) - NOS 36
Vomiting 25
Lack of efficacy - NOS 21
Death by euthanasia 21
Lethargy (see also Central nervous system depression in 'Neurological') 21
Anorexia 20
Accidental exposure 19
Unclassifiable adverse event 15
Behavioural disorder NOS 14
INEFFECTIVE, ANTIBIOTIC 14

Outcome Breakdown

Outcome Unknown
90 (31.4%)
Recovered/Normal
64 (22.3%)
Ongoing
64 (22.3%)
Died
48 (16.7%)
Euthanized
18 (6.3%)
Recovered with Sequela
3 (1.0%)

Data Summary

Metric Value
Total adverse event reports 347
Reports involving death 62
Case-fatality rate (reported events) 1790.0%
Distinct species in reports 10
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Tylosin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 347 adverse event reports referencing Tylosin, including 62 reports in which the animal died — a 1790.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Tylosin. Reported administration routes include Oral, Unknown, Parenteral, Intramuscular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Tylosin reports are Dog (144 reports), Human (51 reports), Unknown (36 reports), with Dog accounting for the largest share. Within those species, Unknown (89), Chicken (unknown) (28), Pig (unknown) (12) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Tylosin are Diarrhoea (51), Death (44), Lack of efficacy (bacteria) - NOS (36), Vomiting (25). Of the 287 reports with a coded outcome, Outcome Unknown is the leading category at 31.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Tylosin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial